CUMYL-PICA (SGT-56) is an
indole-3-carboxamide based
synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of
SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal
synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the
Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as an
agonist for the
cannabinoid receptors, with
Ki values of 59.21 nM at
CB1 and 136.38 nM at
CB2 and
EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2.[3][4]
^Ametovski A, Macdonald C, Manning JJ, Haneef SA, Santiago M, Martin L, et al. (November 2020). "Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA". ACS Chemical Neuroscience. 11 (21): 3672–3682.
doi:
10.1021/acschemneuro.0c00591.
PMID33054155.
S2CID222821806.
CUMYL-PICA (SGT-56) is an
indole-3-carboxamide based
synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of
SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal
synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the
Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as an
agonist for the
cannabinoid receptors, with
Ki values of 59.21 nM at
CB1 and 136.38 nM at
CB2 and
EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2.[3][4]
^Ametovski A, Macdonald C, Manning JJ, Haneef SA, Santiago M, Martin L, et al. (November 2020). "Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA". ACS Chemical Neuroscience. 11 (21): 3672–3682.
doi:
10.1021/acschemneuro.0c00591.
PMID33054155.
S2CID222821806.